围手术期替雷利珠单抗联合新辅助化疗治疗可切除非小细胞肺癌:RATIONALE-315随机试验最终分析
RATIONALE-315是一项随机双盲III期试验,评估围手术期替雷利珠单抗联合新辅助化疗对比单纯新辅助化疗在可切除II-IIIA期NSCLC中的疗效与安全性。最终分析(中位随访38.5个月)显示,替雷利珠单抗组OS显著改善(HR 0.65,95%CI 0.45-0.93,P=0.009),36个月OS率79.3% vs 69.3%,EFS亦显著改善(HR 0.58,95%CI 0.43-0.79)。安全性可耐受。
要点
- 围手术期替雷利珠单抗联合化疗较单纯化疗显著改善OS(HR 0.65)和EFS(HR 0.58)。
- 36个月OS率替雷利珠单抗组79.3%,安慰剂组69.3%。
- 安全性可耐受,与已知各药物安全性一致。
核心结论
- 新辅助替雷利珠单抗联合化疗及辅助替雷利珠单抗较单纯新辅助化疗在可切除II-IIIA期NSCLC中显示统计学显著且临床意义的OS获益和持续EFS改善。
研究设计与样本
- 随机、双盲、III期试验,在中国成人患者中1:1随机接受围手术期替雷利珠单抗或安慰剂联合新辅助化疗,共453例(替雷利珠单抗组226例,安慰剂组227例)。
主要发现
- 最终分析中位随访38.5个月,替雷利珠单抗组OS显著优于安慰剂组(HR 0.65,95%CI 0.45-0.93;P=0.009),两组中位OS均未达到。
- 36个月OS率替雷利珠单抗组为79.3%,安慰剂组为69.3%。
- 替雷利珠单抗组中位EFS未达到,安慰剂组为30.6个月(HR 0.58,95%CI 0.43-0.79)。
- 生存获益在各亚组中基本一致。
- 替雷利珠单抗联合化疗的安全性可耐受,与已知各药物安全性一致。
临床怎么用
- 结果支持在可切除II-IIIA期NSCLC患者中使用围手术期替雷利珠单抗联合新辅助化疗及辅助替雷利珠单抗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative immunotherapy, particularly anti-programmed cell death protein 1 therapy, combined with neoadjuvant chemotherapy has emerged as one of the standard-of-care options for resectable non-small-cell lung cancer (NSCLC). We report the final analysis of RATIONALE-315, a randomized, double-blind, phase III trial evaluating the efficacy and safety of perioperative tislelizumab plus neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in patients with resectable, stage II-IIIA NSCLC. PATIENTS AND METHODS: Adult patients in China were randomized (1 : 1) to receive either perioperative tislelizumab or placebo in combination with neoadjuvant chemotherapy. The dual primary endpoints were event-free survival (EFS) and major pathological response, assessed by blinded independent central review. The secondary endpoints included pathological complete response, overall survival (OS), disease-free survival, and safety. RESULTS: In total, 453 patients were randomized (226 to tislelizumab and 227 to placebo). At the final analysis (median study follow-up of 38.5 months), patients in the tislelizumab group experienced statistically significantly improved OS versus those in the placebo group {hazard ratio (HR) 0.65 [95% confidence interval (CI) 0.45-0.93]; P = 0.009}. The median OS was not reached in either group. The 36-month OS rate was 79.3% in the tislelizumab group versus 69.3% in the placebo group. The median EFS was not reached in the tislelizumab group versus 30.6 months in the placebo group [HR 0.58 (95% CI 0.43-0.79)]. Survival benefits were generally consistent across subgroups. The safety profile of tislelizumab plus chemotherapy was tolerable and consistent with known profiles of the individual therapies. CONCLUSIONS: Neoadjuvant tislelizumab plus chemotherapy and adjuvant tislelizumab demonstrated a statistically significant, clinically meaningful OS benefit and sustained, clinically meaningful EFS improvement compared with neoadjuvant chemotherapy, with a tolerable safety profile in patients with resectable stage II-IIIA NSCLC. These results support the use of this regimen in this patient population. CLINICAL TRIAL NUMBER: NCT04379635.
引用
- Wang C, Wang W, Liu H, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial. Ann Oncol. 2025. PMID: 41344593. doi:10.1016/j.annonc.2025.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。